Dysregulated δNp63α inhibits expression of ink4a/arf, blocks senescence, and promotes malignant conversion of keratinocytes

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Ha, Linan ^a   Ponnamperuma, Roshini M ^a   Jay, Steven ^b   Ricci, M Stacey ^a   Weinberg, Wendy C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2D; HETEROCHROMATIN PROTEIN 1; HETEROCHROMATIN PROTEIN 1 GAMMA; PROTEIN KINASE B; PROTEIN P63; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; RAS PROTEIN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BENIGN TUMOR; CELL AGING; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; KERATINOCYTE; LENTIVIRINAE; LENTIVIRUS INFECTION; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; SKIN CARCINOGENESIS; SKIN PAPILLOMA; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CELL STRAIN HEK293; CELL TRANSFORMATION; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHENOTYPE; TIME;

ANIMALS; CELL AGING; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P19; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; KERATINOCYTES; LENTIVIRUS; MICE; PHENOTYPE; RAS PROTEINS; TIME FACTORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 79960305340     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021877     Document Type: Article

References (50)

1. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, et al. (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305-316.
2. Levine AJ, Oren M, (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9: 749-758.
3. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, et al. (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713.
4. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, et al. (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718.
5. Candi E, Rufini A, Terrinoni A, Dinsdale D, Ranalli M, et al. (2006) Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice. Cell Death Differ 13: 1037-1047.
6. Truong AB, Kretz M, Ridky TW, Kimmel R, Khavari PA, (2006) p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes & Development 20: 3185-3197.
7. DeYoung MP, Ellisen LW, (2007) p63 and p73 in human cancer: defining the network. Oncogene 26: 5169-5183.
8. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, et al. (2000) AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 97: 5462-5467.
9. Wrone DA, Yoo S, Chipps LK, Moy RL, (2004) The expression of p63 in actinic keratoses, seborrheic keratosis, and cutaneous squamous cell carcinomas. Dermatol Surg 30: 1299-1302.
10. Lin Z, Nan Y, Zhang X, Zhao Y, Kim C, et al. (2006) Reverse transcription-polymerase chain reaction and western blotting analysis for detection of p63 isoforms in uterine cervical cancers. International Journal of Gynecological Cancer 16: 1643-1647.
11. Nylander K, Coates PJ, Hall PA, (2000) Characterization of the expression pattern of p63 alpha and delta Np63 alpha in benign and malignant oral epithelial lesions. Int J Cancer 87: 368-372.
12. Nylander K, Vojtesek B, Nenutil R, Lindgren B, Roos G, et al. (2002) Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 198: 417-427.
13. Mooi WJ, Peeper DS, (2006) Oncogene-induced cell senescence- Halting on the road to cancer. New England Journal of Medicine 355: 1037-1046.
14. Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, et al. (2005) BRAF(E600)-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720-724.
15. Keyes WM, Wu Y, Vogel H, Guo XC, Lowe SW, et al. (2005) p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes & Development 19: 1986-1999.
16. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, et al. (2005) Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7: 363-373.
17. Keyes WM, Vogel H, Koster MI, Guo X, Qi Y, et al. (2006) p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci U S A 103: 8435-8440.
18. Ghioni P, Bolognese F, Duijf PH, van Bokhoven H, Mantovani R, et al. (2002) Complex Transcriptional Effects of p63 Isoforms: Identification of Novel Activation and Repression Domains. Mol Cell Biol 22: 8659-8668.
19. Helton ES, Zhu JH, Chen XB, (2006) The unique NH2-terminally deleted (Delta N) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the Delta N variant of p63. Journal of Biological Chemistry 281: 2533-2542.
20. King KE, Ponnamperuma RM, Yamashita T, Tokino T, Lee LA, et al. (2003) ΔNp63α functions as a positive and negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes. Oncogene 22: 3635-3644.
21. Chen YK, Hsue SS, Lin LM, (2004) Expression of p63 (TA and deltaN isoforms) in human primary well differentiated buccal carcinomas. Int J Oral Maxillofac Surg 33: 493-497.
22. Pruneri G, Pignataro L, Manzotti M, Carboni N, Ronchetti D, et al. (2002) p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. Lab Invest 82: 1327-1334.
23. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, et al. (2009) TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 11: 1451-1457.
24. Gressner O, Schilling T, Lorenz K, Schulze SE, Koch A, et al. (2005) TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 24: 2458-2471.
25. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, et al. (2006) p63 protects the female germ line during meiotic arrest. Nature 444: 624-628.
26. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR, (2004) p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 18: 126-131.
27. Koster MI, Lu SL, White LD, Wang XJ, Roop DR, (2006) Reactivation of developmentally expressed p63 isoforms predisposes to tumor development and progression. Cancer Res 66: 3981-3986.
28. Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, et al. (2007) TAp63 and Delta Np63 in cancer and epidermal development. Cell Cycle 6: 274-284.
29. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW, (2006) p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9: 45-56.
30. Koster MI, Dai D, Marinari B, Sano Y, Costanzo A, et al. (2007) p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci U S A 104: 3255-3260.
31. Zhu L, Rorke EA, Eckert RL, (2007) DeltaNp63alpha promotes apoptosis of human epidermal keratinocytes. J Invest Dermatol 127: 1980-1991.
32. King KE, Ponnamperuma RM, Gerdes MJ, Tokino T, Yamashita T, et al. (2006) Unique domain functions of p63 isotypes that differentially regulate distinct aspects of epidermal homeostasis. Carcinogenesis 27: 53-63.
33. Hayflick L, (1965) The Limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37: 614-636.
34. Narita M, Narita M, Krizhanovsky V, Nunez S, Chicas A, et al. (2006) A novel role for high-mobility group A proteins in cellular senescence and heterochromatin formation. Cell 126: 503-514.
35. Su XH, Cho MS, Gi YJ, Ayanga BA, Sherr CJ, et al. (2009) Rescue of key features of the p63-null epithelial phenotype by inactivation of Ink4a and Arf. Embo Journal 28: 1904-1915.
36. Ponnamperuma RM, King KE, Elsir T, Glick AB, Wahl GM, et al. (2009) The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGF-beta-mediated growth regulation. Journal of Pathology 219: 263-274.
37. Tremain R, Marko M, Kinnimulki V, Ueno H, Bottinger E, et al. (2000) Defects in TGF-beta signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras. Oncogene 19: 1698-1709.
38. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, et al. (2010) The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2: 344-352.
39. Leontieva OV, Blagosklonny MV, (2010) DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY) 2: 924-935.
40. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW, (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a). Cell 88: 593-602.
41. Campisi J, (2001) Cellular senescence as a tumor-suppressor mechanism. Trends in Cell Biology 11: S27-S31.
42. Romano RA, Ortt K, Birkaya B, Smalley K, Sinha S, (2009) An active role of the DeltaN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One 4: e5623.
43. Koster MI, Huntzinger KA, Roop DR, (2002) Epidermal differentiation: transgenic/knockout mouse models reveal genes involved in stem cell fate decisions and commitment to differentiation. J Investig Dermatol Symp Proc 7: 41-45.
44. Pozzi S, Zambelli F, Merico D, Pavesi G, Robert A, et al. (2009) Transcriptional network of p63 in human keratinocytes. PLoS One 4: e5008.
45. King KE, Ponnamperuma RM, Allen C, Lu H, Duggal P, et al. (2008) The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth. Cancer Res 68: 5122-5131.
46. Perez CA, Pietenpol JA, (2007) Transcriptional programs regulated by p63 in normal epithelium and tumors. Cell Cycle 6: 246-254.
47. Boldrup L, Coates PJ, Gu X, Nylander K, (2009) DeltaNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of Cox-2 as a novel p63 target. J Pathol 218: 428-436.
48. Weinberg WC, Montano NE, Deng C, (1997) Loss of p21CIP1/WAF1 does not recapitulate accelerated malignant conversion caused by p53 loss in experimental skin carcinogenesis. Oncogene 15: 685-690.
49. Frost SJ, Simpson DJ, Clayton RN, Farrell WE, (1999) Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G(1) arrest in the AtT20 pituitary tumor cell line. Molecular Endocrinology 13: 1801-1810.
50. Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, et al. (2007) ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A 104: 10968-10973.